Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investo ...

Core Viewpoint - Braze's stock is experiencing a decline following analysts' reductions in price targets, yet the company is recognized for its growth potential in the AI sector [1][2]. Group 1: Analyst Actions - Stifel analyst Parker Lane has lowered Braze's price target from $45 to $40 while maintaining a buy rating, citing the company's overlooked competitive advantages [1]. - Last week, Piper Sandler also reduced its price target for Braze from $50 to $30, keeping an overweight rating on the stock [2]. Group 2: Financial Performance - In Q3 2025, Braze reported a 25% year-over-year increase in revenue, with free cash flow of $17.8 million, a significant improvement from negative free cash flow of $14.2 million in the same period last year [3]. Group 3: Valuation Metrics - Braze shares are currently trading at 2.7 times sales, which is below the five-year average price-to-sales ratio of 6.2, indicating that the stock is undervalued [4].

Amazon.com, Inc. ( AMZN ) has experienced a hefty sell-off of ~15% following their latest earnings. This was mainly fueled by investor anxiety caused by the company's massive plans to spend $200 billion CapExGerman Buy-Hold-Check investor. With a master's degree in engineering and management, I am able to understand, quantify, and interpret both the economics and (to some point) the technology of companies.Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMZN either through stock ...

Amazon.com, Inc. ( AMZN ) has experienced a hefty sell-off of ~15% following their latest earnings. This was mainly fueled by investor anxiety caused by the company's massive plans to spend $200 billion CapExGerman Buy-Hold-Check investor. With a master's degree in engineering and management, I am able to understand, quantify, and interpret both the economics and (to some point) the technology of companies.Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMZN either through stock ...

PresentationAll right. Thank you, everyone, for being here with us. I am Michael Ward, North American Life Insurance analyst at UBS. Very happy to have Voya with us today. We have Heather Lavallee and Mike Katz, CEO and CFO, and we're very excited to be here today. So we'll get right to it. I figured, Heather and Mike, we could start with some key messages after the 4Q into '26.Heather LavalleePresident, CEO & Director Yes, I'll start. And I think the first is that we had an exceptional year in '25. You loo ...

Core Viewpoint - Workday Inc announced a leadership change with co-founder Aneel Bhusri returning as CEO, leading to a more than 6% drop in shares, raising concerns among analysts regarding the timing and implications of this decision [2][3][4]. Group 1: Leadership Change - Aneel Bhusri will replace Carl Eschenbach as CEO, who has served in this role for the past three years and will remain as a strategic advisor [2]. - The leadership change comes shortly after the end of the fiscal Q4, which has raised questions about the timing [3][4]. Group 2: Analyst Concerns - Analysts at Jefferies expressed skepticism about the leadership transition, suggesting that it raises questions about the company's direction, especially since Bhusri previously handed over the CEO role to focus on product and AI [4]. - There are concerns that this move may indicate potential further management changes and doubts about Workday's ability to meet medium-term targets, particularly in light of slowed growth and potential margin pressures [4]. - Analysts are awaiting more clarity on the situation during Workday's earnings release scheduled for February 24 [5].

From a built-in nugget ice maker to forward-thinking laundry technology, Whirlpool is setting a new market standard with its latest appliance lineup. BENTON HARBOR, Mich., Feb. 9, 2026 /PRNewswire/ -- This February at the Kitchen and Bath Industry Show (KBIS), Whirlpool brand is proving that high-tech doesn't have to mean high-complexity. At the Whirlpool Corporation Booth (#W701), the brand will debut tech-first products designed to be as practical and intuitive as they are innovative. Industry-Firsts That ...

This morning, I woke up to a stunning report that Google is gearing up to sell a 100-year bond. That follows a similar move in early November, when Google issued a 50-year bond.Investors are giving this company billions and are willing to wait up to a century to get it back. In contrast, the US government usually borrows money for a maximum of 30 years. And the interest rates Google is paying are not that much more than what the US Treasury pays. For the 50-year bond, Google paid about 1 percentage point ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Kyndryl Holdings, Inc. ("Kyndryl†or the "Company†) (NYSE: KD) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON KYNDRYL HOLDINGS, INC. (KD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 9, 2026, Kyndryl announced the Company's CFO and Gene. ...

Key Takeaways AZN will report Q4 results on Feb. 10, with cancer and diabetes drugs expected to drive quarterly sales.INCY and VRTX's Q4 results to be supported by Jakafi growth and CF drug demand, respectively.GILD and MRNA look to product portfolio strength as vaccine and liver disease sales shape results.The fourth-quarter earnings season continues to be in full swing this week, with many large drugmakers like AstraZeneca (AZN) , Incyte (INCY) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) and ...